These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 17107389)

  • 1. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K; Prins C; Saurat JH; French LE
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of primary cutaneous B-cell lymphoma with rituximab.
    Fink-Puches R; Wolf IH; Zalaudek I; Kerl H; Cerroni L
    J Am Acad Dermatol; 2005 May; 52(5):847-53. PubMed ID: 15858476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
    Morales AV; Advani R; Horwitz SM; Riaz N; Reddy S; Hoppe RT; Kim YH
    J Am Acad Dermatol; 2008 Dec; 59(6):953-7. PubMed ID: 18817999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
    Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
    Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
    Bonnekoh B; Schulz M; Franke I; Gollnick H
    J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
    Kyrtsonis MC; Siakantaris MP; Kalpadakis C; Dimopoulou MN; Vassilakopoulos TP; Kontopidou FN; Antoniou C; Korkolopoulou P; Panayiotidis P; Pangalis GA
    Eur J Haematol; 2006 Oct; 77(4):300-3. PubMed ID: 16856917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab].
    Gamo R; Calzado L; Pinedo F; López-Estebaranz JL
    Actas Dermosifiliogr; 2008 May; 99(4):291-6. PubMed ID: 18394405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma.
    Peñate Y; Hernández-Machín B; Pérez-Méndez LI; Santiago F; Rosales B; Servitje O; Estrach T; Fernández-Guarino M; Calzado L; Acebo E; Gallardo F; Salar A; Izu R; Ortiz-Romero PL; Pujol RM; Fernández-de-Misa R
    Br J Dermatol; 2012 Jul; 167(1):174-9. PubMed ID: 22356294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.
    Lacouture ME; Baron JM; Jani AB; Laumann AE; Soltani K
    Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.
    Heinzerling LM; Urbanek M; Funk JO; Peker S; Bleck O; Neuber K; Burg G; von Den Driesch P; Dummer R
    Cancer; 2000 Oct; 89(8):1835-44. PubMed ID: 11042581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cutaneous B-cell lymphoma treatment with rituximab: two cases].
    Viguier M; Bachelez H; Brice P; Rivet J; Dubertret L
    Ann Dermatol Venereol; 2002 Oct; 129(10 Pt 1):1152-5. PubMed ID: 12442128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas.
    Brandenburg A; Humme D; Terhorst D; Gellrich S; Sterry W; Beyer M
    Br J Dermatol; 2013 Nov; 169(5):1126-32. PubMed ID: 23796422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Low-grade cutaneous B-cell lymphoma: Failure of intralesional rituximab (Mabthera)].
    Abasq C; Duval-Modeste AB; Courville P; Joly P
    Ann Dermatol Venereol; 2008; 135(6-7):509-11. PubMed ID: 18598807
    [No Abstract]   [Full Text] [Related]  

  • 15. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
    Strauss SJ; Morschhauser F; Rech J; Repp R; Solal-Celigny P; Zinzani PL; Engert A; Coiffier B; Hoelzer DF; Wegener WA; Teoh NK; Goldenberg DM; Lister TA
    J Clin Oncol; 2006 Aug; 24(24):3880-6. PubMed ID: 16864854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
    Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
    Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
    J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Litchy S; Barton JH; Houston GA; Hermann RC; Bradof JE; Greco FA;
    J Clin Oncol; 2003 May; 21(9):1746-51. PubMed ID: 12721250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
    Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
    Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.